Compare Abeona Therapeutics Inc (ABEO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs RLX Technology Inc — how do they compare? Abeona Therapeutics Inc trades at $7.36 (market cap $421.19M), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 5.7× Abeona Therapeutics Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RLX | |
|---|---|---|
Market Cap | $421.19M | $2.42B |
Sector | Health | Technology |
52-Week High | $7.45 | $2.73 |
52-Week Low | $4.17 | $1.79 |
Enterprise Value | $276.10M | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
RLX trades at $2.01, up 0.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with a net income margin of 22.47% in 2026. Recent news highlights its Q2 2026 earnings call scheduled for August 14, 2026, focusing on European integration.
The outlook is mixed: strong international revenue growth and solid profitability support upside, but consecutive earnings misses and a single analyst's hold rating indicate caution. Key risks include regulatory scrutiny in the vaping industry and execution challenges in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
